I think a big reason a partner didn't step up for
Post# of 72440
(Total Views: 173)
Posted On: 01/07/2017 6:40:03 PM
I think a big reason a partner didn't step up for Absssi is because a generic version of Cubicin (Dapto) has already been approved by the FDA and at least one of it's patents expires September 24, 2019;
Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
So with the probability that Dapto is going generic before B Absssi would be approved, and no guarantee that they wont come up with an oral formulation for it, I think it was wise to go with B-OM and B-UP and with P until the coffers can afford a longer term and expensive PIII trial. K will need some nurturing as well but my confidence is high with the new highers and I'm comfortable with our starting lineup.
Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
So with the probability that Dapto is going generic before B Absssi would be approved, and no guarantee that they wont come up with an oral formulation for it, I think it was wise to go with B-OM and B-UP and with P until the coffers can afford a longer term and expensive PIII trial. K will need some nurturing as well but my confidence is high with the new highers and I'm comfortable with our starting lineup.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼